GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Cyclically Adjusted PB Ratio

AEterna Zentaris (AEterna Zentaris) Cyclically Adjusted PB Ratio : 0.02 (As of Apr. 28, 2024)


View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Cyclically Adjusted PB Ratio?

As of today (2024-04-28), AEterna Zentaris's current share price is $1.9562. AEterna Zentaris's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $81.33. AEterna Zentaris's Cyclically Adjusted PB Ratio for today is 0.02.

The historical rank and industry rank for AEterna Zentaris's Cyclically Adjusted PB Ratio or its related term are showing as below:

AEZS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.07   Max: 1
Current: 0.02

During the past years, AEterna Zentaris's highest Cyclically Adjusted PB Ratio was 1.00. The lowest was 0.01. And the median was 0.07.

AEZS's Cyclically Adjusted PB Ratio is ranked better than
97.04% of 641 companies
in the Biotechnology industry
Industry Median: 1.72 vs AEZS: 0.02

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

AEterna Zentaris's adjusted book value per share data for the three months ended in Dec. 2023 was $3.747. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $81.33 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


AEterna Zentaris Cyclically Adjusted PB Ratio Historical Data

The historical data trend for AEterna Zentaris's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Cyclically Adjusted PB Ratio Chart

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 - 0.12 0.02 0.02

AEterna Zentaris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.02

Competitive Comparison of AEterna Zentaris's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, AEterna Zentaris's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEterna Zentaris's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Cyclically Adjusted PB Ratio falls into.



AEterna Zentaris Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AEterna Zentaris's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.9562/81.33
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AEterna Zentaris's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, AEterna Zentaris's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=3.747/125.4675*125.4675
=3.747

Current CPI (Dec. 2023) = 125.4675.

AEterna Zentaris Quarterly Data

Book Value per Share CPI Adj_Book
201403 726.858 98.604 924.880
201406 442.721 99.473 558.412
201409 282.595 99.394 356.726
201412 552.824 98.367 705.128
201503 562.700 99.789 707.496
201506 129.004 100.500 161.052
201509 58.915 100.421 73.609
201512 54.425 99.947 68.322
201603 41.035 101.054 50.949
201606 22.765 102.002 28.002
201609 8.129 101.765 10.022
201612 12.022 101.449 14.868
201703 9.741 102.634 11.908
201706 6.969 103.029 8.487
201709 -2.973 103.345 -3.609
201712 -4.232 103.345 -5.138
201803 17.595 105.004 21.024
201806 14.461 105.557 17.189
201809 11.268 105.636 13.383
201812 2.900 105.399 3.452
201903 -5.413 106.979 -6.348
201906 -4.551 107.690 -5.302
201909 -2.742 107.611 -3.197
201912 -3.080 107.769 -3.586
202003 1.797 107.927 2.089
202006 0.987 108.401 1.142
202009 6.042 108.164 7.009
202012 5.269 108.559 6.090
202103 13.242 110.298 15.063
202106 12.644 111.720 14.200
202109 12.341 112.905 13.714
202112 10.912 113.774 12.034
202203 10.947 117.646 11.675
202206 11.181 120.806 11.612
202209 10.177 120.648 10.584
202212 7.368 120.964 7.642
202303 6.427 122.702 6.572
202306 5.988 124.203 6.049
202309 5.412 125.230 5.422
202312 3.747 125.468 3.747

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AEterna Zentaris  (NAS:AEZS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AEterna Zentaris Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (AEterna Zentaris) Business Description

Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.